One of the best ways to keep up with Likarda and follow us in the national and local news is by browsing our recent news articles and media mentions.

Buzz for BIO: Moving Early-Phase Discovery Forward with Confidence

By | News & Media | No Comments

Custom 3D Assays and Research Services Result in Better Predictability of Drug Treatment Response

Using our proprietary 3D screening approach, Likarda researchers test different drugs with known effects in humans using the conventional pharmaceutical approach and our 3D cell cluster. In each case, the results of our 3D assays better mimicked how the drugs work in humans. Compared to conventional methods, our process allows you to better predict responses to drug treatments. And as a CRO, our turnaround time and costs are more efficient.

Likarda develops and works with 3D models in cancer, diabetes, stem cells, liver, and several other areas. We can develop cell-based assays tailored to a specific cell type of interest, whether it is human, animal, cell lines or other source of origin.

384 Vs. 200,000
Our approach to 3D cell-based testing is highly efficient, allowing us to return results with speed and accuracy. While others can create and test 384 cell clusters in a normal cell culture microplate, our proprietary micromold forms and tests 200,000 clusters in the same space.

Likarda routinely conducts assay development for projects ranging from a disease model to searching for a specific mechanism of action. Our clients, large and small, rely on us to design assay systems that answer questions to guide them to the next stage, or not.

We’re known for accurate, high-quality results across all phases of drug discovery and development, including:

  • Toxicology
  • Metabolism
  • Cell health assays
  • ADME & Pharmacodynamics
  • Assay Development
  • Histology and Immunohistochemistry
  • Preclinical animal studies
  • Mass spectrometry
  • Analytical chemistry

Other services:


BIO 2017 Register nowLet’s Schedule a Meeting to Discuss Your Custom 3D Assay Project

Karthik Ramachandran, PhD, our vice president of strategic growth & co-founder, will be at BIO in San Diego in June. Schedule a meeting with him to discuss how our custom 3D cell-based assay approach or other services can confidently move your discovery research forward.

Meet us at BIO

Lindsey Ott Delivers Well Received Poster Session on Likarda’s New 3d Liver Spheroid System at 2016 AAPS Annual Meeting

By | News & Media | No Comments

Likarda’s product innovation scientist, Lindsey Ott, Ph.D., was a presenting author for a poster session at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition on November 16 in Denver, CO. Session attendees learned about a promising three-dimensional cell-based method to evaluate liver metabolism and toxicity for early stage drug discovery via Likarda’s 3D liver spheroid system. Read More

Testing Drug Toxicity and Curing Disease Using Three-Dimensional Cell Clusters

By | News & Media | No Comments

For decades, tests to understand how the body works, and how it responds to drugs have been conducted with a single layer of cells attached to a plastic petri dish. In other words, the testing system critical to discovering cures operates in a 2D environment. Therein lies the problem. We live in a 3D world, and our bodies are made up of cells attached to each other in a moving 3D structure. 2D testing isn’t a true predictor of how cells react to drugs, but it’s used because it has been the available option. Read More